Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320379 | 1.00 | HCAR2 (0.51) | HCAR2KDM4EMAPTTSHRKMT2A | |
| SCHEMBL3320374 | 1.00 | HCAR2 (0.51) | HCAR2KDM4EMAPTTSHRKMT2A | |
| SCHEMBL3883004 | 0.91 | HCAR2 (0.56) | HCAR2KDM4EMAPTTSHRKMT2A | |
| SCHEMBL7309367 | 0.87 | HCAR2 (0.53) | HCAR2KDM4EMAPTTSHRKMT2A | |
| SCHEMBL19277737 | 0.86 | HCAR2 (0.51) | HCAR2KDM4EMAPTTSHRKMT2A | |
| SCHEMBL2167275 | 0.84 | GPR139 (0.45) | TSHRKMT2AALDH1A1CYP3A4 | |
| SCHEMBL5402590 | 0.84 | CRHBP (0.54) | KDM4ETSHRKMT2AMTNR1AMTNR1B | |
| SCHEMBL28472584 | 0.84 | HCAR2 (0.53) | HCAR2KDM4EMAPTTSHRKMT2A | |
| SCHEMBL5493235 | 0.84 | ALDH1A1 (0.46) | MAPTTSHRKMT2AMTNR1AMTNR1B | |
| SCHEMBL29016877 | 0.84 | HCAR2 (0.53) | HCAR2KDM4EMAPTTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865739-B2 | Substituted heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140107155-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8664399-B2 | Substituted heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130102632-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20100125091-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | US | disclosed |
| EP-1505156-B1 | Process for the enantioselective preparation of secondary alcohols by lipase catalysed solvolysis of the corresponding acetoacetic acid ester | CONSORTIUM ELEKTROCHEM IND (DE) | 2005-12-07 | — | — | EP | disclosed |
| US-20050032182-A1 | Process for the enantioselective preparation of secondary alcohols by lipase-catalyzed solvolysis of the corresponding acetoacetic esters | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH | 2005-02-10 | — | — | US | disclosed |
| EP-1505156-A1 | Process for the enantioselective preparation of secondary alcohols by lipase catalysed solvolysis of the corresponding acetoacetic acid ester | Consortium für elektrochemische Industrie GmbH (DE) | 2005-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107155-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNH2, KCNJ2, CACNA1E | HCAR2 268/4885KDM4E 1527/4885MAPT 4101/4885 |
| US-20100125091-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNH2, KCNJ2, CACNA1E | HCAR2 268/4885KDM4E 1527/4885MAPT 4101/4885 |
| US-20130102632-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNH2, KCNJ2, CACNA1E | HCAR2 268/4885KDM4E 1527/4885MAPT 4101/4885 |
| US-20050032182-A1 | Process for the enantioselective preparation of secondary alcohols by lipase-catalyzed solvolysis of the corresponding acetoacetic esters | LIPC, LIPE, LIPA | HCAR2 1689/4885KDM4E 4077/4885MAPT 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.